Omega-3 fatty acids have one of the better randomized datasets for biological aging. In DO-HEALTH, adults 70 and over taking omega-3 for three years had modestly slower aging on several DNA methylation clocks, roughly three months, with additive effects on one clock when combined with vitamin D and exercise. The analysis was post hoc. But the same trial found no benefit on blood pressure, physical performance or cognition, and large cardiovascular trials such as VITAL were largely null, while high doses raise the risk of atrial fibrillation.
Summary drafted from this entry’s sources; editorial review pending.
01Key questions
Does omega-3 slow biological aging?
Modestly, on clocks. In DO-HEALTH, three years of omega-3 slowed PhenoAge, GrimAge2 and DunedinPACE by about three months, with additive effects alongside vitamin D and exercise (Bischoff-Ferrari et al., Nature Aging 2025).1
Did DO-HEALTH show clinical benefits?
Not for its main outcomes. Omega-3 did not improve blood pressure, physical performance, fracture risk or cognition over three years in the primary trial report (Bischoff-Ferrari et al., JAMA 2020).2
What about heart disease?
The VITAL trial, with nearly 26,000 participants, found no reduction in major cardiovascular events overall (Manson et al., NEJM 2019).3
Are there risks?
A meta-analysis of cardiovascular trials found omega-3 supplements raised atrial fibrillation risk by about 25%, with a larger increase in trials that used more than 1 g per day (Gencer et al., Circulation 2021).4
Marine omega-3 fatty acids (EPA and DHA, from fish oil or algae) are among the most-taken supplements in the world and among the most argued about. Large outcome trials have mostly been disappointing for heart attacks and cancer in the general population. But in 2025 a three-year randomized trial in older Europeans gave omega-3 a different kind of result: it modestly slowed several next-generation epigenetic aging clocks. This entry collects the omega-3 evidence that Heretic otherwise has scattered across a dozen pages, with the clock result in context.
02DO-HEALTH: the clock result
DO-HEALTH randomized 2,157 healthy European adults aged 70 and over to vitamin D, omega-3, a simple home strength programme, all combinations, or placebo, for three years (trial amounts are listed under What studies and practitioners report). A post hoc analysis of 777 participants with blood samples measured four DNA-methylation clocks (PhenoAge, GrimAge, GrimAge2 and DunedinPACE):
- Omega-3 alone slowed PhenoAge, GrimAge2 and DunedinPACE.
- All three interventions had additive benefits on PhenoAge.
- Standardized effects were 0.16 to 0.32 units, about 2.9 to 3.8 months less biological ageing over three years (PMID 39900648).
Three caveats keep this from being a headline: it is a post hoc analysis, not the trial's pre-registered outcome; the effect is small; and epigenetic clocks are surrogate measures whose changes have not yet been shown to translate into longer or healthier lives (see Biological age clocks). One clock author is a founder of a foundation that licenses clock patents, a disclosed interest.
03What the same trial found on clinical outcomes
DO-HEALTH's main results, published in 2020, were null: omega-3 did not significantly improve blood pressure, physical performance, cognitive scores, non-vertebral fractures or infections at three years, though infection rates leaned lower (rate ratio 0.89, 99% CI 0.78 to 1.01) (PMID 33170239). So the clocks moved while the pre-specified clinical endpoints did not. That pattern is common in ageing research and is exactly why clock results should be read as a signal, not proof.
04The wider trial record
| Trial | Population | Result |
|---|---|---|
| VITAL, NEJM 2019 | 25,871 US adults, 5.3 years | No significant reduction in major cardiovascular events (HR 0.92, 95% CI 0.80 to 1.06) or invasive cancer (HR 1.03); total myocardial infarction was lower (HR 0.72, 95% CI 0.59 to 0.90), a secondary endpoint (PMID 30415637) |
| DO-HEALTH, JAMA 2020 | 2,157 Europeans 70+, 3 years | No significant effect on six clinical endpoints (PMID 33170239) |
| DO-HEALTH clocks, Nature Aging 2025 | 777 participants, post hoc | About 3 months less epigenetic ageing over 3 years (PMID 39900648) |
Swipe table →
05Safety: the atrial fibrillation signal
A 2021 meta-analysis of seven cardiovascular outcome trials (81,210 people) found that omega-3 supplements raised the risk of atrial fibrillation by about 25% (HR 1.25, 95% CI 1.07 to 1.46). The risk grew with dose: HR 1.12 in trials using 1 g a day or less and 1.49 in trials using more (PMID 34612056). This matters for anyone taking high-dose fish oil on the assumption that more is better.
06Where it sits on the Heretic scale
Promising for the narrow claim that omega-3 slows epigenetic ageing markers: one well-run randomized trial, small effect, post hoc. It is not evidence that fish oil extends life, and the general-population outcome trials for heart disease and cancer are largely null. What would move it: a pre-registered clock endpoint replicated in a second trial, or clinical outcomes that track the clock change. Related: Daily multivitamin (COSMOS), the other cheap supplement with a 2025-26 clock result; Vitamin D optimization; and Seed oils and inflammation for the omega-6 side of the ledger.
What studies and practitioners report
Amounts as reported in the cited sources: trial doses with the population studied, and practitioner-reported ranges marked as such. Not medical advice.
- Trial 1 g/day · marine omega-3 (EPA plus DHA), 3 years adults 70 and older, DO-HEALTH PMID 39900648
Further reading: detailed protocols
- FoundMyFitness: omega-3 topic overview foundmyfitness.com
07Connections
08Sources
- Bischoff-Ferrari HA, et al. (2025). "Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial." Nat Aging 5(3):376-385. PMID 39900648 . DOI 10.1038/s43587-024-00793-yPubMed 39900648 · DOI 10.1038/s43587-024-00793-y
- Bischoff-Ferrari HA, et al. (2020). "Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults: The DO-HEALTH Randomized Clinical Trial." JAMA . PMID 33170239 . DOI 10.1001/jama.2020.16909PubMed 33170239 · DOI 10.1001/jama.2020.16909
- Manson JE, et al. (2019). "Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer." N Engl J Med . PMID 30415637 . DOI 10.1056/NEJMoa1811403PubMed 30415637 · DOI 10.1056/NEJMoa1811403
- Gencer B, et al. (2021). "Effect of Long-Term Marine Omega-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis." Circulation . PMID 34612056 . DOI 10.1161/CIRCULATIONAHA.121.055654PubMed 34612056 · DOI 10.1161/CIRCULATIONAHA.121.055654
09Entry history
Latest content update.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.